The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients : A comparison

Access this Article

Search this Article

Author(s)

    • KINOSHITA Yasuyuki
    • Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
    • TOMINAGA Atsushi
    • Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
    • USUI Satoshi
    • Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
    • ARITA Kazunori
    • Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University
    • SUGIYAMA Kazuhiko
    • Department of Clinical Oncology and Neuro-oncology Program, Hiroshima University Hospital
    • KURISU Kaoru
    • Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University

Abstract

The arginine + GHRH test has been established as an alternative to the insulin tolerance test (ITT) for the diagnosis of adult GH deficiency (AGHD). However, the glucagon, arginine, and GH releasing peptide-2 (GHRP-2) test are recommended as alternatives in Japan. The objective of this study was to evaluate the arginine and GHRP-2 tests as alternatives to the ITT for the diagnosis of AGHD in a Japanese population. Three stimulation tests (ITT, arginine test, and GHRP-2 test) were conducted in 71 pre-operative adult patients with pituitary tumors (age, 18-65 years). The peak GH responses to each test were examined. The peak GH responses were significantly lower with the ARG test (median 4.43 μg/L) (<i>p</i> < 0.0001) than with the ITT (median 9.38 μg/L), and the peak GH responses with the GHRP-2 test (median 28.88 μg/L) were higher (<i>p</i> < 0.0001). However, among the AGHD patients, there was no significant difference between the peak GH responses to the ARG test and the ITT. The sensitivities and specificities of the ARG / GHRP-2 tests compared to the ITT for the diagnosis of severe AGHD (peak GH responses to ITT ≤ 1.8 μg/L) were 93.8% / 81.3% and 85.5% / 94.5%, respectively. The arginine and GHRP-2 stimulation tests are acceptable alternatives to the ITT for the diagnosis of AGHD in Japanese patients. The method and criterion for the diagnosis of AGHD should be reconsidered and adjusted to each population.

Journal

  • Endocrine Journal

    Endocrine Journal 60(1), 97-105, 2013-01-01

    The Japan Endocrine Society

References:  31

Codes

Page Top